溢多利(300381.SZ):與美國Fornia公司簽訂技術開發合作合同 合作開發創新型酶製劑產品
格隆匯12月17日丨溢多利(300381.SZ)公佈,公司於2021年12月15日與Fornia BioSolutions,Inc.(簡稱“Fornia公司”)在廣東珠海和美國加州簽訂了《技術開發合作合同》,約定雙方合作開發創新型酶製劑產品並達到商業化生產標準,公司向Fornia公司支付項目研究開發經費。雙方約定,技術開發費總額為283萬美元。
Fornia公司是一家美國的高科技生物技術企業,該公司具有完整的微生物和生物酶製劑的研發平台,擁有高通量的篩選設備和大數據分析系統,可高效率地開展生物酶的定向進化、重組表達、微生物菌株的修飾和改良、發酵工藝優化等科研工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.